# A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis

> **NCT05152563** · PHASE3 · WITHDRAWN · sponsor: **Allakos Inc.**

## Conditions studied

- Eosinophilic Gastritis
- Eosinophilic Duodenitis

## Interventions

- **DRUG:** AK002
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT05152563
- **Lead sponsor:** Allakos Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** WITHDRAWN
- **Start date:** 2021-12
- **Primary completion:** 2022-01-20
- **Final completion:** 2022-01-20
- **Target enrollment:** 0 (ACTUAL)
- **Why stopped:** Company decision
- **Last updated:** 2023-03-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05152563

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05152563, "A Study to Assess Subcutaneous AK002 in Eosinophilic Gastritis and/or Eosinophilic Duodenitis". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05152563. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*